This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
Immunotherapy Induced ITP Survey
Share |

Immunotherapy Induced ITP Survey

 

♦ Data Entry ♦

 

Description Abstract:

Immunotherapies used in chronic diseases such as Multiple Sclerosis (alemtuzumab), and malignancies with checkpoint inhibitors (pembrolizumab, nivolumab and others) are increasingly associated with a phenomenon of iatrogenic immune thrombocytopenia.

These complications are thankfully rare (3%), but for this reason, an international collaboration is desperately needed to pool knowledge and experience on the successful, and sometimes unsuccessful, treatment of this complication.

Often, patients have limited alternative options to treat their underlying disease, and increasingly it becomes the prerogative of the consulting hematologist to provide safe means of improving platelet counts so that immunotherapy may be continued. Current expertise is limited to case reports, small case series. Data from clinical trials provide some sense of scope of the problem, but limited guidance for how to manage cases refractory to first-line measures.

 

If you wish to participate in the questionnaire, please visit the Immunotherapy Induced ITP Survey.

 

For any questions, please feel free to contact Dr. Philip Choi at: Phil.Choi@act.gov.au.

 

Membership Management Software Powered by YourMembership  ::  Legal